medicine
Tuesday, October 15, 2024
Stamford – In the manufacturer’s phase 4 study, monthly injections of the CGRPR antibody erenumab helped up to two-thirds of patients with analgesic or migraine (MOH) overuse significantly reduce their painkiller consumption. The placebo effect was surprising, according to results published in JAMA Neurology (2024; DOI: 10.1001/jamaneurol.2024.3043). Almost one percent of adults…